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H eart failure is increasing worldwide in part due to an aging iml)ulation. In l)aticnts with heart fail- 
ure, the heart often dilates to compensate for the de- 
creased cardiac function. But the dihlted cllamber 
radius of the failing heart increases wall stress in 
l,rOl,ortion to the ventricular radius, according to 
Lal,hlce's law (Fig IA). This increased wall stress in- 
duces fitrtller cllallfl,er dilation and (leterioration in 
cardiac fimction. Surgical relno,leling operations, in- 
cluding endoventricular 1,arch plasty repair (Dot" pro- 
ccdure) for ischcmic cardiolnyoi,athy and lmrtial left 
ventriculcctomy (PLV; Batista procedure) for dilated 
cardiomyolmthy , reverse this vcntricular emodeling 
process. PLV decreases the ventricular adius by re- 
sccting a large part of the left ventricle (LV). This 
1,roccdure has had a high faihlre rate, however, partly 
l,ecause it requires major surgery on cartliopuhnonary 
bylmss and removes a large segment of otherwise viable 
muscle. The procedure may also worsen diastolic fimc- 
tion even though systolic fimction iml,roves. 
A novel device, the Myosplint (Myocor, Inc., Mal)le 
Grove, MN), has been developed to change the shal,e of 
the LV and make the effective radius smaller without 
resecting vial)le muscle (Fig IB). We typically apply 
20% stress rc,hlction l,y tightening tile Myosl)lint so 
that the new radius (R2) is 80% of tile original radius 
(R1). The Myosplint iml)roves ventricular fimction i)y 
reducing wall stress and increasing contractility. Com- 
1,are(l with tile atnount of radius re(lllctioll, tile rcsuh- 
ing vohnne re,hlction is less. Therefore, tile Myosl)lint 
is not expected to creatc nmjor changes in diastolic 
filnction. 
Tile concel)t of tile Myosplint is ilhlstrated in Fig II. 
Two people hohl two different-sized sails in tile same 
strength wind. Tile force required to hohl the hlrge sail 
is higher because of larger radius of the sail. If a post is 
solidly fixed in the ground in the middle of the sail, then 
the force rcquircd to hohl the large sail wouhl be much 
smaller because of the smaller effective radius. 
In the dilated heart, shal)e change is acllicvcd l)y 
placing three equally spaccd Myosplints along a line 
froln the llasc to the apex, as ilhlstratcd in Fig III. The 
goal is to place each of thc Myosl)lints such that they 
cqually l)iscct tile LV chamber in the cross-scctional 
planc while avoiding damage to the valvular al)lmratus 
and coronary vcsscls. A variety of positions arc possi- 
l)Ic, lint the lnOSt comnlon l)ositioll is from the latcral 
wall (just mc(lial or lateral to the antcrolatcral papil- 
lary muscle) to tile posterior SCl)tum. This position was 
chosen to facilitate Myosl)lint insertion while avoiding 
injury to cl)icardial and intraventricular structures. 
Patients diagnosed with dilated cartliomyol)athy are 
apllrol)riatc candidates for this l)rocedure. The LV 
end-diastolic diameter determined by two-dimcnsiolml 
echocardiogral)hy shouhl 1)refcrably be between 6.5 
and 12 cm. The New York Heart Association (NYItA) 
classification can be III or early class IV. Patients with 
sustained or uncontrolled atrial and/or ventricular ar- 
rhythmia, active infection, or acute myocardial infarc- 
tion (within 30 clays) are not approl)riate candidates. 
The Myosl)lint consists of an iml)lantable transven- 
tricular tension melnl)cr and two epicardial pads (Fig 
IVA). The 1.4-ram diameter l)olycthylcnc braided 
tension member is coated with exl)andcd polytetra- 
lhlorocthylcne (e-PTFE). The tension member is cx- 
trelnely durable, as evidenced by its freedom froln 
structural deterioration at 200 million cycles (5 
years) of accelerated life testing. This tension mem- 
l)er is connected to a fixed epicardial pad constructed 
from high-perfornmnce engineering thermol)lastic 
and covered with polyester fabric. A similar adjust- 
able epicardial pad is threaded over and fixed to tile 
tension member after iml)lantation. The two pads are 
l)hlccd on opposite surfaces of the heart, with the 
load-l)earing tension nmlnlmr l)assing through tile 
LV, connecting tile l)ads and drawing tile ventricular 
walls toward one another. 
Several surgical instruments have been specifically 
designed to facilitate iml)lantation. Tile EpiProl)e 
(Fig IVB) is used in combination with el)icardial 
echocardiogral)hy (EEl to identify the desired loca- 
tion for Myosl)lint ll lacemcnt relative to internal and 
external cardiac anatomy by coml)ressing the el)icar- 
dial surface to create an endocardial indentation. 
The EpiTag (Fig IVB) is a marker deployed from the 
tip of the El)iProbe to mark tile entry and exit i)oints 
on the surface of the heart. The C-alignment device 
(C-device) is a surgical instrunmnt used to guide tile 
needle and style( asseml)ly from the entry to tile exit 
points of tile ventricle for precise delivery of the 
tension mcmbers (Fig IVC). The C-device has a guide 
tube to guide the ldacement of the needle and stylet 
asseml)ly in one end and a hard stop to stop advance- 
ment of the needle and style( asseml)ly after place- 
ment through the ventricle in the other end. The 
needle and stylet asseml)ly (Fig IVC), comprising a
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Fig I. (A) Accor,ling to Laplace's law wall, stress (T) in tile dilated heart is directly related to tile ventricular radius (R1) and 
intraventrieular l, essure (P) and inversely related to wall thickness (h). (B) The Myosplint creates a bilobular shape with 
reduced wall stress due to the reduced effective radius of each lobe (R2). 
needle tube and a superelastic styler, is used with the 
C-device to create a pathway through the ventricle to 
deliver the tension member. The measurement and 
tightening (M/T) device is used to measure the epi- 
eardial distance of the heart and to apply the 20% 
stress reduction (Fig IVD). LV dimension is initially 
obtained by reading the position of the green index 
mark on the pr imary (black) scale of the M/T device. 
To apply the 20% stress reduction, the green index 
mark is adjusted to the same value on the second 
(blue) scale as is measured on the black scale. 
Conl lnents  
The Myosplint improves ventricular fimction by reduc- 
ing wall stress and increasing contractility. 1,2 Cardiac 
OUtlmt does not increase dramatically after Myosplint 
implantation unlike after ventricular assist device im- 
plantation. Therefore, postoperative management is
similar to that for a lmticnt with heart failure. In 
addition, tlle administration of anticoagulation therapy 
(warfarin to an international normalized ratio of 2 .0 -  
3.5) for 90 days is recommended. 
Other surreal  approaches to treating diiated cardio- 
myollathy inchide Ileart transplantation, mechanical 
assistance devices, lnitral valve repair, PLV, and dy- 
namic cardiomyoplasty. New devices, such as Acorn's 
(Acorn Cardiovascular, Inc., St. Paul, 5IN) cardiac 
support device (CSD) 3 and the CardioClasp t (Cardio- 
Clasp, Inc., Somerville, NJ) have also been developed 
to treat dilated cardiomyolmthy. 
Iteart transplantation is a highly effective therapy 
for l)atients with end-stage heart failure; however, it is 
severely limited by the shortage of donor hearts, which 
is expected to never meet the overwhchning demand. 
hnplantable left ventricular assist devices (LVADs) 
have demonstrated clilfical success in treating lmticnts 
with end-stage heart failure mainly as a bridge to trans- 
plant. 5 Recipients of these portable electrically pow- 
Fig II. Tile concept of tile Myosplint call best 
be understood by conceiving of two peol,le hohl- 
ing a sail. (A) Small sail. (B) Large sail. (C) 
Large sail with a post solidly fixed in tile ground 
ill tile middle of tile sail. 
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92 FUKAMACIII ET AL 
Fig Ill. Thrcc transvcntricular Myosplints are placed along 
a line from the base to the apex to bisect the ventricle. 
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Fig IV. (A) The Myosplint (a tension member with fixed and adjustable cpieardial pads). (B) The EpiProbe. and EpiTag. 
(C) The C-device and needle and stylct asscmbly. (D) The 5I/T device. 
TIlE MYOSIq.INT 1311'I~N'i" PI{OCEI)UI{E 93 
SURGICAL TECllNIQUE 
J 
EpiProb~ 
EpiTag 
Aorta " 
RAappendage 
c 
t_z' 
Echo probe . ;  .~- -~_-  -~. 9 2oo~ 
1 The 5Iyosplint implantation procedure is pcrfornwd through a median sternotomy incision 
without tile use of cardiolmlmonary bypass. When concomitant procedures, uch as mitral valve 
repair, are pcrfllrmcd, Myosplint implantation can be performed either before going on cardio- 
pulmonary bypass or after weaning from the bypass. Tlre implant procedure includes three distinct 
phases: (1) identification of positions and marking, (2) Myosplint placcmcnt, and (3) shape change 
I)FOCCSS. 
Tile first step is to identify tire desired insertion points for tire three tension nlcml)crs. Tile 
pcricardiunl is lifted with pericardial stitches for better exposure of tile LV lateral wall and tile 
right ventricular (RV) posterior wall. Tire goal is to place each of the tension members o that tile)" 
equally bisect tire LV chamber in the cross-sectional p ane while avoiding damage to the valvular 
al)l)aratus and coronary vessels. These three tension mcmlJcrs houhl be equally Slmccd along a line 
from base to tile apex. First, the entry lloints on tile LV are identified; then the corresponding exit 
l)oints on the RV are identified. Tire entry points relative to tire internal structures, such as 
lmpillary muscles, arc identified by imaging with EE in tire short axis. We use an ElfiProbe to 
compress tire epicardial surface and create an cndocardial indentation (indicated by tile arrow in 
the echocardiographic image) to correlate the internal anatomy and cxtcrnal positions of the pads. 
Once tire positiorl is determined, an EpiTag, which sticks on tile epicardimn, is deployed fi'om the 
till of the ElliProbe (inset). 
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2 This illustration shows all six EpiTags in place. Tile first (lmsal) LV position is 
alllH'oximatcly 3 cm below tile atriovcntricular groove, and medial (or lateral) to tile 
antcrolatcral papillary muscle. Tile second (middle) LV position is allproximatcly 3 cm 
below the first position, just medial (or lateral) to the anterolateral papillary muscle. 
The third (apical) LV position is approximately 3 cm below the second position, placed 
parallel to the first two positions, running in the direction of the apex. The first (basal) 
RV 1,osition is approximately 3 cm below the atrioventricular g oove and approximately 
2 cm from the posterior descending artery at a level and an orientation that yiehl good 
lliscction and avoid damage to tile valvular apllaratus and cllicardial vessels. The 
second (middle) RV position is approximately 3 cm l)elow tile first position in the 
direction of tile apex parallel to the line created by the basal positioning. The third 
(apical) RV position is apllroximatcly 3 cm l~elow the second position, placed parallel to 
the first two positions and running in the direction of tile apex. 
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3 After all tension member locations arc determined, the tension mcnd~ers are placed ill tile 
followillg order: basal, middle, aml apical. A specially designed C-,levice is llsc,l to allow precise 
,lelivcry of the tension members and to stabilize the beating heart during tile delivery of a flexible 
needle and styler assembly from the cntry to the exit point. The needle aml stylet assembly is loaded 
into the guide till, e of the C-device. The C-device is then placed armmd tile heart, with the tip of 
each eml of the C-device located at the l,rcdctermincd entry aml exit poiIlts with El,iTags. The 
C-device is placed so that the side with the guide tube is l,laccd on the LV entry point. 
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4:  Tile needle and stylet assembly is inserted through the LV entry point, throvgh the 
chamber, and out the RV until tile needle hits the hacd stop (see inset) of the C-device. 
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Needle clamp 
After the needle and stylct assembly is placed, the needle tube is grasped with a needle clmnp 
and tile stylet is removed fi'om tile needle tul,e. Tile flexil,le needle tube is pulled through tile heart 
to allow easy access to tile end of the needle tube for placing the tension mend~er. 
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6 Once tile needle tube is secured, the C-device is detached from the guide tube and removed 
from the chest cavity. EpiTags are removed by pulling on the attached leader. 
Tension member 
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7 Tile tension member has a leader segment on one end and a fixed pad on tile other end. 
The leader segment of tile tension member is inserted into tile distal end of the needle tube and 
fed through the length of the needle tube. Once the tension member leader exits through tile 
needle tube, the needle tube is removed, leaving the tension member traversing the ventric- 
ular walls and chambers. The tension member is pulled through the heart until the pad rests 
against he RV wall (see inset). 
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After placement, short-axis EE confirms tension member 1,ositioning and chaml,cr bisec- 
lion. If tension member placement is not acccl,tal,lc , then the tension member is removed and 
repositioncd. Acccptal,lc placcmcnt is judged by avoidance of major coronary vessels, papil- 
lary muscles, and valvular structures and l)y apl)rolwiatc bisection of the. LV. 
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9 A delfloyable pad and a measurement and tightening (M/T) device are 
placed over the end of tile tension meml,er. The M/T device is advanccd until 
both pads rest on the outside of the heart (see inset). The M/T device is adjusted 
until any potential distance between the RV wall and septum is collapsed (as can 
be seen on the EE) without changing the LV geometry. In this l,osition, the M/T 
device measures the pretightening LV dimension by reading the position of the 
green index mark on the primary (black) scale. 
TIlE 31YOSI'LINT IMI'I.ANT PROCEI)URE 99 
Blue scale 
s 
I I I I  I I I I I I I I  , ,  i t t l  , I J l ,  , h i .  
ImTmlm ImTmln ' I " " I , L 'qU ' I ' , . ImTmI" 'NTWI*L . I I~H|WI | J J~ IU J J~~ 
t i l l  
Black scale F 
IO The process fl~r tension member insertion is repeated for the middle and apical tension 
recruiters. Starting with the lmsal tension ,nembcr, the M/T device is tightened to apply the 20% 
stress reduction. The green index marl,: is adjusted to the same value on the second (l)lue) scale as 
is measured on the black scale. Fine and coarse adjustment when using the M/T device and handling 
the black phmger enables large size adjustments initially and then finer tuning for precise 
measurement. The. tightening procedure is repeated for all tension members. 
l l After all three tension nlcmbcrs are tightened, EE is relwrformed to conf i rm the shape 
change and to evaluate mitral and tricuspid valve regurgitation. 
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12 To lock the deployable ind in place, the delivery hub of the deployable 
lind is rotated clockwise until two clicks are heard. Any excess tension member 
is trimmed with a cautery device (an electric "hot knife") through the trimming 
window of the M/T device. 
l~  Oil complelion of tile Myosplint implantation procedure, tile heart has 
been succcssfldly reshal)cd by tightening the three tension mcmhers. 
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ered devices can become outpatients and achieve an 
acccl)tablc quality of life. Myosplint iml)lantation is not 
recommended for such severely ill, end-stage heart fail- 
ure l)aticnts. 
In patients with dilated cardiomyol)athy , func- 
tional mitral regurgitation often results from annular  
dilatation and ventricular enlargement. Bolling and 
colleagues 6 showed that 1)aticnts with severe vcntric- 
ular dysfunction and scvcrc mitral regurgitation im- 
1)rove clinically after mitral valve repair alone and 
rcl)ortcd actual 1- and 2-year survival rates of 82% 
and 71%, respectively. In our experience in 44 l)a - 
ticnts with mitral regurgitation and an LV ejection 
fraction below 35% who underwent isolated mitral 
repair (n = 35) or replacement (n = 9), the 1-, 2-, 
and 5-year survival rates were 89%, 86%, and 67%, 
respectively, with an iml)rovenmnt in NYIIA class 
from 2.8 + 0.8 preoperatively to 1.2 _+ 0.5 at follow- 
Ul). 7 The Myosl)lint iml)lantation can be performed in 
combination with mitral valve repair for patients 
with dilated cardiomyol)athy and mitral regurgita- 
tion. 
PLV reduces wall stress and improves ystolic func- 
tion by resecting a large part of the LV muscle. Itow- 
ever, PLV is a major surgical procedure requiring 
cardiol)uhnonary b pass and loss of a large segment of 
otherwise viable myocardium; thc procedure may also 
worsen 1)rccxisting diastolic dysfunction, a In our expe- 
rience in 62 l)aticnts at the Cleveland Clinic, we ol)- 
served a significant early failure rate, with 60% 3-year 
survival and 26% freedom from failure. 9Ahhough im- 
provements in subjective clinical status and objective 
llleflslirClllClltS (maximum exercise oxygen consli lnp- 
lion) are ol)scrved in some patients, PLV currently is 
not considered to l)c a prcdictal)le, reliable ahcrnativc 
to transl)lantation. 
The Myosplint has several 1)ossiblc advantages. It
can be easily iml)lantcd on a beating heart; reduces wall 
stress without resccting otherwise viable muscle; im- 
proves systolic function without creating major changes 
in diastolic function; and does not require a power 
SOIIFCe. 
A newly designed C-(lcvicc is being cvaluatcd clin- 
ically to further  improve the iml)lantation proce- 
dure. This new C-device has two separate arms, one 
arm with a guide tul)e and another arm with a hard 
stop (Fig VA). Each arm is adjusted to the entry or 
exit point independently,  and a vacuum is applied to 
ensure the attachment of each arm onto the el)tear- 
dial surface. The two arms are then connected 1)y 
aligning the handles. The two handles are snapped 
together to lock in place (Fig VB). The handle can 
then l)c used to stabilize the C-device during the 
delivery of the needle assembly through the chaml)cr. 
With the current one-piece C-device, one end some- 
times lllOVCS as the surgeon adjusts the other end. We 
Fig V. The new C-device has two selmratc arms to allow 
independent adjustment of the l)osition of each end. 
anticipate that the new C-device will be used in 
future Myosl)lint implantat ion surgeries. 
The Myosplint is a passive device for treating 
dilated cardiomyol)athy and is easily applied on a 
1)eating heart. The device is now being evaluated 
clinically in Germany and the United States as an 
adjunct for those needing valve surgery or as the sole 
surgical therapy for patients with idiol)athic eardio- 
myol) athy. 
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